Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform For the first time, Firefly also unveils a new strategic initiative to build the world’s first foundation model of the human brain using its BNA™ technology KENMORE, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health out ...

- University of Waterloo’s Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for an exciting new brain model initiative to be revealed soon - KENMORE, N.Y., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes f ...

Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change, driving innovation in brain health Company highlights its potentially transformative role in Neuropharmacology and Psychiatry with two groundbreaking publications KENMORE, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solution ...

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday.The Dow traded down 0.21% to 42,216.81 while the NASDAQ fell 0.55% to 18,982.63. The S&P 500 also fell, dropping, 0.39% to 5,813.49.Check This Out: Top 3 Utilities Stocks That Could Lead To Your Biggest Gains This MonthLeading and Lagging SectorsConsumer discretionary shares rose by 1.3% on Tuesday.In trading on Tuesday, health care shares tumbled by 1%.Top HeadlineU.S. producer prices rose 0.2 ...

Company Overview - Firefly Neuroscience Inc is an AI company focused on developing innovative solutions to improve brain health outcomes for patients with neurological and mental disorders [5] - The company's FDA-cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD [5] - Firefly has built a comprehensive database of brain wave tests over 15 years, securing patent protection and achieving FDA clearance [5] - The company is now commercially launching BNA™, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use [5] Technology Innovation - Firefly's BNA™ technology platform utilizes Resting EEG and Cognitive EEG (ERP) data to assess patients' brain age, marking the first instance where cognitive data measured by ERP has been successfully utilized for assessing biological brain age [2] - The BNA™ system was developed using AI and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal EEGs of over 17,000 patients representing twelve disorders, as well as clinically normal patients [8] - BNA™, in conjunction with an FDA-cleared EEG system, provides clinicians with comprehensive insights into brain function, enhancing their ability to accurately diagnose mental and cognitive disorders and evaluate optimal therapies [8] Research Advancement - Firefly announced the advancement of research to assess a patient's brain age via its FDA-cleared BNA™ technology platform, potentially paving the way for a proactive and scalable approach to early screening and monitoring for Alzheimer's patients [1] - The BNA™ data assessment can identify significant disparities between brain age and chronological age, which could serve as a valuable risk factor for dementia [2] - This breakthrough underscores the company's commitment to pushing the boundaries of innovation in brain health, aiming to make a meaningful impact on patients' lives [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 FIREFLY NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | --- | |----------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------- ...

Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company’s dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, tod ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share AIFF Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ ...

TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024. To schedule a one-on-one investor meeting with managem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-41092 FIREFLY NEUROSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 54-1167364 (State or other jurisdiction of incorporation or organization) (I. ...